Pionyr’s team was searching for a CDMO partner to help develop its immuno-oncology therapeutics. Leaning on past positive interactions, Alicia and her team landed on Lonza as a manufacturing partner.
Pionyr’s team was searching for a CDMO partner to help develop its immuno-oncology therapeutics. Leaning on past positive interactions, Alicia and her team landed on Lonza as a manufacturing partner.
While at a Big Pharma, Simon Westbrook had an idea for a complex fusion chimera protein he believed could interrupt the neurotrophin pathway and have a profound impact on chronic pain and joint degeneration in osteoarthritis patients. He formed Levicept and went on to partner with Lonza to bring his idea to fruition.
It’s been two years since the initial launch of “Lonza & Me.” We’re excited to continue to continue to offer campaign support to Lonza into 2023 and beyond.
Surrozen is a small biotech developing novel and complex bispecific antibodies that target activation of the WNT pathway to take advantage of its regenerative potential. Although the WNT pathway has been studied for decades, Surrozen — following a partnership with Lonza — is aiming to develop the first therapeutics that intervene in this pathway, and only in diseased tissue.
Our team worked with Alicia Levey, and Kiren Khanduja from Pionyr Immunotherapeutics. Thank you both for your time and for taking part in the latest rendition of Lonza & Me.